Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20929925 | 0.92 | NLRP3 (0.46) | NLRP3MEN1ALDH1A1KMT2ACA2 | |
| SCHEMBL19505716 | 0.88 | NLRP3 (0.47) | NLRP3IDH1CA2 | |
| SCHEMBL19505713 | 0.88 | NLRP3 (0.39) | NLRP3CA2 | |
| SCHEMBL19505715 | 0.85 | NLRP3 (0.37) | NLRP3CA2 | |
| SCHEMBL6555753 | 0.84 | NLRP3 (0.66) | NLRP3 | |
| SCHEMBL19505946 | 0.83 | NLRP3 (0.52) | NLRP3CA2 | |
| SCHEMBL29551031 | 0.83 | NLRP3 (0.52) | NLRP3CA2 | |
| SCHEMBL20930017 | 0.82 | NLRP3 (0.46) | NLRP3IDH1CA2 | |
| SCHEMBL7622551 | 0.80 | NLRP3 (0.60) | NLRP3 | |
| SCHEMBL19506004 | 0.78 | NLRP3 (0.48) | NLRP3KMT2AIDH1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760735-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-09-19 | — | — | US | disclosed |
| US-11760735-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-09-19 | — | — | US | disclosed |
| US-11760735-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-09-19 | — | — | US | disclosed |
| US-20230099258-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11339136-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2022-05-24 | — | — | US | disclosed |
| US-11339136-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2022-05-24 | — | — | US | disclosed |
| EP-3445757-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RES INC (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3445757-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RES INC (US) | 2020-11-25 | — | — | EP | disclosed |
| US-20190119224-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2019-04-25 | — | — | US | disclosed |
| US-20190119224-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2019-04-25 | — | — | US | disclosed |
| WO-2017184624-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230099258-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NLRP3 2/4885MEN1 3469/4885ALDH1A1 2031/4885 |
| US-11760735-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | NLRP3 2/4885MEN1 3469/4885ALDH1A1 2031/4885 |
| US-20190119224-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NLRP3 2/4885MEN1 3469/4885ALDH1A1 2031/4885 |
| US-11339136-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | NLRP3 2/4885MEN1 3469/4885ALDH1A1 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.